An observational study in - Aortic Aneurysm, sponsored by Hopital Jean Minjoz. Status unknown. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2013-08-08.
Sponsored by Hopital Jean Minjoz · Observational
We aimed to see if aortic aneurysms could be followed-up by circulating endothelial progenitor cells CD34+144+CD14- and CD34+VEGF-R2+CD14- blood level.
Circulating endothelial progenitor cells CD34+144+CD14- and CD34+VEGF-R2+CD14- have been shown to be inversely correlated to aortic aneurysm size. We aimed to see if aortic aneurysms could be followed-up by circulating endothelial progenitor cells CD34+144+CD14- and CD34+VEGF-R2+CD14- blood level. 40 patients followed for known aortic aneurysm >30mm and \<50mm will be followed up every 6 months during 2 years. Each 6 months they will have a consultation by their physiologist with an echo or a CT-scan. At the same time, a 10ML blood sample will be taken to assess the circulating endothelial progenitor cells CD34+144+CD14- and CD34+VEGF-R2+CD14- blood level.
960 studies on the registry are indexed under Aneurysm; 175 are open to participants now.
This study's planned enrollment of 40 is below the median of 151 across 443 observational studies indexed under Aneurysm.
Browse Aneurysm studies →Hopital Jean Minjoz is the lead sponsor of 5 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with aortic aneurysm
Exclusion Criteria:
Patients with aortic aneurysm \>30mm and \< 50mm
Circulating endothelial progenitor cells CD34+144+CD14- and CD34+VEGF-R2+CD14- blood concentration
Patients are followed for 2 years
Time frame: 2 years
No study locations are listed for this record.
This study is status unknown, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hopital Jean Minjoz